Johnson & Johnson Vision, a global leader in eye health and part of the Johnson & Johnson Medical Devices Companies, received Health Canada approval for the first and only daily disposable contact lens for vision correction in patients who experience itchy allergy eyes due to allergic conjunctivitis: ACUVUE® Theravision™ with Ketotifen. The lens contains an H1 histamine receptor antagonist for the prevention of itchy allergy eyes associated with allergic conjunctivitis experienced by contact lens users to promote comfortable contact lens wear. In March 2021, ACUVUE® Theravision™ with Ketotifen received its first regulatory approval from the Japanese Ministry of Health, Labour and Welfare.
“We are proud to mark another step forward in delivering this important innovation to help relieve patients from allergic eye itch while continuing to comfortably wear contact lenses,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision***. “We look forward to working with additional health authorities to make ACUVUE® Theravision™ with Ketotifen available to more patients around the world.”
Itchy allergy eyes can impact vision, and this becomes even more problematic for contact lens wearers – most of whom resort to rubbing their eyes.ǂ Data show that nearly 8 out of 10 contact lens wearers feel frustrated when their eye allergies interfere with normal contact lens wear.§ ACUVUE® Theravision™ with Ketotifen may help people continue to wear their contact lenses for vision correction, and prevent allergic eye itch, without the need for allergy eye drops.
ACUVUE® is the most trusted brand for eye care professionals globally^ and has built a legacy by making contact lenses that are unbeaten in comfort, across 47 clinical studies.† ACUVUE® Theravision™ with Ketotifen is the latest in a long line of innovative contact lenses from Johnson & Johnson Vision since the company introduced the world’s first daily disposable soft contact lens three decades ago. ACUVUE® Theravision™ with Ketotifen is the first in an entirely new contact lens category and brings forward a better contact lens wearing experience for patients with allergic eye itch.
About ACUVUE® Theravision™ with Ketotifen
ACUVUE® Theravision™ with Ketotifen contact lenses are a daily disposable contact lens for correcting refractive ametropia (myopia and hyperopia) in phakic or aphakic patients who are suitable for contact lens wear and experience ocular allergic itch due to allergic conjunctivitis and who do not have red eye(s) or more than 1.00 D of astigmatism. The lens contains an H1 histamine receptor antagonist for the prevention of itch associated with allergic conjunctivitis experienced by contact lens users to promote comfortable contact lens wear. The prevention of itch has been demonstrated to last through 12 hours in clinical trials; however, the lens may be worn for longer than 12 hours for vision correction. Pediatrics (12 years of age and older): The safety and efficacy of ACUVUE® Theravision™ with Ketotifen in pediatric patients has been established.
About Johnson & Johnson Vision*
At Johnson & Johnson Vision*, part of Johnson & Johnson Medical Devices Companies, we have a bold ambition: to change the trajectory of eye health worldwide. Through our operating companies, we deliver innovation that enables eye care professionals to create better outcomes for patients throughout their lives, with products and technologies that address unmet needs including refractive error, cataracts, and dry eye. In communities with greatest need, we work in collaboration to expand access to quality eye care, and we are committed to helping people see better, connect better, live better. Visit us at jjvision.com, follow @JNJVision on Twitter, Johnson & Johnson Vision on LinkedIn, and @JNJVision on Facebook.
About Johnson & Johnson Medical Devices Companies**
At Johnson & Johnson Medical Devices Companies, we are helping people live their best lives. Building on more than a century of expertise, we tackle pressing healthcare challenges, and take bold steps that lead to new standards of care while improving people’s healthcare experiences. In surgery, orthopaedics, vision, and interventional solutions, we are helping to save lives and paving the way to a healthier future for everyone, everywhere.